No link between type I interferon autoantibody positivity and adverse reactions to COVID-19 vaccines.

ABSTRACT: Type I interferons act as gatekeepers against viral infection, and autoantibodies that neutralize these signaling molecules have been associated with COVID-19 severity and adverse reactions to the live-attenuated yellow fever vaccine. On this background, we sought to examine whether autoantibodies against type I interferons were associated with adverse events following COVID-19 vaccination. Our nationwide analysis suggests that type I interferon autoantibodies were not associated with adverse events after mRNA or viral-vector COVID-19 vaccines.

SUBMITTER: Yalcinkaya A 

PROVIDER: S-EPMC10883980 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature